US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Clearmind Medicine Inc (CSE:CMND)

N/A UNCHANGED
Last Price Updated: 3:54 PM EDT, Mar 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc

< Previous 1 2 3 4 Next >
News headline image
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Applies to Cease Being a Reporting Issuer in Canada
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine CEO Issues Letter to Shareholders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents ↗
SciSparc & Clearmind file patents for LSD, psilocybin, DMT blends, advancing psychedelic therapeutics for mental health. 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
From Clearmind Medicine Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0) Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement
Via Investor Brand Network
News headline image
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Completed Type A Meeting with the FDA
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces 1-for-30 Reverse Share Split
From Clearmind Medicine Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >